SOURCE: Kadmon Corporation
NEW YORK, NY--(Marketwired - Jan 8, 2014) - Kadmon Corporation, LLC, today announced that Samuel D. Waksal, Ph.D., its Chairman and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 11:00 a.m. PT at the Westin St. Francis in San Francisco, CA. Dr. Waksal will provide an overview of Kadmon and its commercial and clinical programs.
About Kadmon Corporation
Kadmon Corporation, LLC, is a fully integrated biopharmaceutical company, focused on the development of drugs that target unmet medical needs in areas of serious disease, including oncology, infectious diseases, immunology and neurodegenerative diseases. Kadmon is developing a portfolio of drugs in mid-stage clinical development and a number of monoclonal antibodies undergoing preclinical testing emphasizing emerging concepts in molecular biology and genomics. Kadmon distributes and markets a portfolio of branded and generic drugs for hepatitis C including proprietary high dose ribavirin formulations which are supported by a specialty US sales force with well-established prescriber relationships and unparalleled access to specialty pharmacies. Kadmon is based in New York, New York, with operations in Warrendale, Pennsylvania and Boston, Massachusetts. For more information, visit www.kadmon.com.